Takeda/Lundbeck depression candidate Brintellix outshines Servier's agomelatine
This article was originally published in Scrip
Lundbeck has released data from the European Phase III REVIVE trial of its novel multimodal investigational depression pill Brintellix (vortioxetine, formerly known as Lu AA21004, partnered with Takeda for the US/Japan) showing it meets the primary efficacy endpoint of statistically significant superiority to Servier's Valdoxan (agomelatine). Both drugs are positioned as new alternatives for patients who have failed to respond adequately to conventional SSRI/SNRI treatments.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.